Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMOVAL: Valganciclovir Prophylaxis in Kidney Transplant
NCT03123627Phase 3Completed
- Sponsor
- Maimónides Institute of Biomedical Research of Córdoba
- Start
- Aug 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valganciclovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Maimónides Institute of Biomedical Research of Córdoba. Primary endpoint: Incidence of CMV disease at 12 months after transplantation. Started Aug 2016; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03123627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123627.